S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:ILMNIllumina Stock Price, Forecast & News

$399.33
-1.41 (-0.35 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$393.13
Now: $399.33
$403.66
50-Day Range
$358.94
MA: $376.42
$400.74
52-Week Range
$196.78
Now: $399.33
$404.20
Volume835,167 shs
Average Volume1.19 million shs
Market Capitalization$58.70 billion
P/E Ratio62.89
Dividend YieldN/A
Beta0.99
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
Illumina logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$8.35 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Employees7,700
Market Cap$58.70 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$399.33
-1.41 (-0.35 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock been impacted by COVID-19 (Coronavirus)?

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ILMN stock has increased by 62.3% and is now trading at $399.33.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Illumina?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Illumina
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) released its quarterly earnings results on Thursday, April, 30th. The life sciences company reported $1.64 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.25 by $0.39. The life sciences company had revenue of $859 million for the quarter, compared to the consensus estimate of $857.92 million. Illumina had a net margin of 26.48% and a return on equity of 21.78%. The company's revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $1.60 earnings per share.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

14 brokers have issued 12 month target prices for Illumina's shares. Their forecasts range from $290.00 to $390.00. On average, they anticipate Illumina's share price to reach $343.36 in the next twelve months. This suggests that the stock has a possible downside of 14.0%.
View analysts' price targets for Illumina
.

Has Illumina been receiving favorable news coverage?

News articles about ILMN stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Illumina earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the life sciences company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Illumina
.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Walt Disney (DIS), salesforce.com (CRM), Visa (V), Micron Technology (MU), Gilead Sciences (GILD) and Baidu (BIDU).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 66)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
  • Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Copper Rock Capital Partners LLC (1.59%), Jennison Associates LLC (1.17%), Sumitomo Mitsui Trust Holdings Inc. (0.78%), Swiss National Bank (0.40%), Principal Financial Group Inc. (0.30%) and Douglas Lane & Associates LLC (0.24%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Kornitzer Capital Management Inc. KS, Jennison Associates LLC, Waverton Investment Management Ltd, PGGM Investments, TCW Group Inc., KAMES CAPITAL plc, and Gateway Investment Advisers LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
.

Which institutional investors are buying Illumina stock?

ILMN stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, First Trust Advisors LP, Envestnet Asset Management Inc., Principal Financial Group Inc., Dock Street Asset Management Inc., CWM LLC, SG Americas Securities LLC, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Illumina
.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $399.33.

How big of a company is Illumina?

Illumina has a market capitalization of $58.70 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.